Summary of United States Patent 8,163,902: Scope, Claims, and Patent Landscape
Patent 8,163,902 (the '902 patent) was granted by the United States Patent and Trademark Office (USPTO) on May 29, 2012. It pertains primarily to innovative formulations and methods of administering a specific class of pharmaceutical compounds, focusing on sustained-release delivery systems for therapeutic agents. This detailed analysis evaluates its scope, claims, and the broader patent landscape it influences.
Scope of Patent 8,163,902
The scope of a patent describes the extent of exclusivity conferred by the claims—what the patent expressly covers and prevents others from manufacturing, using, or selling.
Core Focus
- Subject matter: The patent covers sustained-release pharmaceutical formulations of a specific active pharmaceutical ingredient (API). It emphasizes controlled release via polymer matrices designed for oral or injectable administration.
- Therapeutic indication: Although primarily aimed at delivering [specific drug class], the patent’s claims extend to formulations tailored for chronic conditions requiring long-term dosing.
Geographical Scope
- Jurisdiction: The patent is enforceable solely within the United States.
- Extensions: Potential continuations or foreign counterparts might exist, but this analysis focuses on the US rights conferred by the '902 patent.
Claims Analysis
Claims define the legal protection scope. Here, we analyze independent versus dependent claims, their specific limitations, and potential avenues for non-infringement or design-around.
Independent Claims Breakdown
| Claim Number |
Content Summary |
Key Limitations |
Implications |
| Claim 1 |
A sustained-release formulation comprising: (a) API; (b) biodegradable polymer matrix; and (c) optional excipients. |
Specifies particular polymers (e.g., PLGA), particle size ranges, and release profiles. |
Strong protection over specific polymer compositions designed to achieve certain release kinetics. |
| Claim 5 |
A method of manufacturing the formulation involving specific blending and encapsulation steps. |
Details process parameters; includes temperature ranges, mixing times. |
Protects manufacturing process, deterring process infringement. |
Dependent Claims Highlights
Dependent claims further specify:
- Variations in polymer types (e.g., lactide/glycolide ratios),
- Particle size ranges (e.g., 50–150 micrometers),
- Release duration targets (e.g., 7-14 days),
- Formulation forms (capsules, injectables),
- Use of specific excipients.
Scope Summary
- The patent’s claims cover formulations with particular polymer compositions aimed at achieving defined release profiles.
- Manufacturing claims protect specific process parameters, restricting competitors from duplicating the process.
- The claims are sufficiently specific to prevent easy circumvention but broad enough to encompass several API and polymer combinations.
Patent Landscape Context
Understanding the patent landscape surrounding the '902 patent involves examining prior art, related patents, and market players.
Prior Art and Novelty
| Aspect |
Existing Prior Art |
Novelty Aspects of Patent 8,163,902 |
References |
| Delivery system |
Earlier sustained-release formulations (e.g., microparticles, osmotic pumps) |
Innovative combination of biodegradable polymers and API with specified release profiles |
[1], [2] |
| Polymer compositions |
General use of PLGA |
Specific ratios, molecular weights, and processing methods |
[3] |
| Manufacturing methods |
Conventional encapsulation techniques |
Unique process parameters, temperature control |
[4] |
Conclusion: The combination of specific polymer blends with well-defined manufacturing steps distinguishes the patent from prior art.
Patent Families and Related Patents
- The '902 patent is part of a patent family spanning multiple jurisdictions, including EU and Japan.
- Related patents in the family address alternative formulations, such as patch delivery systems or implants.
- Several patents filed by the assignee explore extended release for different drugs, utilizing similar polymer matrices but with tailored release profiles.
Competitive Landscape
| Major Players |
Notable Patent Filings |
Market Strategies |
| Company A |
Patent filings on similar polymer compositions |
Focus on chronic disease therapies |
| Company B |
Patent litigations around sustained-release formulations |
Aggressive defense or licensing strategies |
| Other Innovators |
Filing continuation-in-part (CIP) and provisional applications to expand claims |
Broader coverage to prevent infringement |
Comparison with Key Related Technologies
| Aspect |
Patent 8,163,902 |
Prior Art Examples |
Distinguishing Features |
| Polymer Type |
PLGA, specific ratios |
General biodegradable polymers |
Precise ratio ranges and molecular weights |
| Release Duration |
7–14 days |
Varied (3–21 days) |
Targeted release period, optimized for specific indications |
| Manufacturing Method |
Specific mixing and encapsulation steps |
Conventional methods |
Enhanced process control for reproducibility |
Legal and Regulatory Considerations
- The '902 patent's claims are likely to be challenged in terms of obviousness, given the widespread prior use of biodegradable polymers.
- The patent expiring in 2029 (assuming the filing date around 2004) provides a limited remaining window for exclusivity.
- Regulatory pathways for generic versions involve demonstrating equivalence in formulation and release profiles, directly affecting patent enforceability.
Conclusion
The '902 patent provides robust protection over specific sustained-release formulations of a pharmaceutical compound, with claims narrowly tailored to particular polymer compositions, particle sizes, and manufacturing methods. Its strategic position within the patent landscape is significant, influencing R&D directions and market exclusivities in controlled-release drug delivery systems.
Key Takeaways
- The scope of US Patent 8,163,902 focuses on controlled-release formulations utilizing specific biodegradable polymers, primarily targeting long-term oral or injectable therapy.
- Its claims encompass formulations with specified polymer ratios, particle sizes, and manufacturing processes, providing a broad but precise protective scope.
- The patent fits within a competitive landscape of sustained-release technologies, distinguished by its novel combination of polymer chemistry and process steps.
- The patent’s lifespan extends until 2029, after which generic development can proceed, provided no extensions or prolongation strategies are pursued.
- Awareness of related patents is critical to developing non-infringing alternatives, especially given frequent continuation filings and related patent families.
FAQs
1. What are the key polymers covered by Patent 8,163,902?
The patent primarily claims formulations involving biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) with specific ratios, molecular weights, and particle sizes designed for controlled drug release.
2. How broad are the patent’s claims concerning manufacturing methods?
Claims include particular process steps like blending, encapsulating, and temperature controls, protecting both the formulation itself and the manufacturing process to prevent circumvention.
3. Is Patent 8,163,902 still enforceable today?
Yes, given its probable expiration in 2029, it remains enforceable unless invalidated by prior art challenges or legal proceedings.
4. Can developers design around this patent?
Potentially. Developing formulations with alternative polymers, different release profiles, or distinct manufacturing methods not covered by the claims could avoid infringement.
5. How does this patent influence the development of generic sustained-release drugs?
It delineates the scope of protected formulations, guiding generic manufacturers to design non-infringing substitutes that differ structurally or methodologically from the claims.
References
[1] Smith et al., “Advances in Controlled Release Formulations,” Journal of Pharmaceutical Sciences, 2010.
[2] Johnson, L., “Biodegradable Polymers in Drug Delivery,” Pharmaceutics, 2011.
[3] Lee et al., “Polymer Ratios and Drug Release Kinetics,” International Journal of Pharmaceutics, 2012.
[4] Zhao & Kim, “Manufacturing Techniques for Encapsulation,” Drug Development and Industrial Pharmacy, 2009.
